Entities / Company
Hoffmann-La Roche.
Swiss healthcare company
- Reports this week
- 6
- Active events
- 10
- Connections
- 924
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Well supported6 reports1 development inside
-
Hoffmann-La Roche opened a new R&D center in Boston.Some support3 reports1 development inside
-
Nvidia and Hoffmann-La Roche share interest in AI-driven therapeutics following the establishment of a new innovation center in Boston.Some support1 report
-
Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.Some support1 report
-
Earendil Labs collaborates with Genentech.Some support1 report
-
Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.Some support1 report1 development inside
-
Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.Some support1 report
-
LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.Some support1 report
-
Arvinas secured capital via a Genentech partnership, AdvanCell appointed a new CFO, and Johanna Mylet served as an audit manager.Some support1 report
-
China's rise in vitamin production is putting pressure on European companies, highlighted by the divestment of Roche's vitamins division.Some support2 reports
Earlier this month
-
A company involving Hoffmann-La Roche is facing imminent closure and 100 redundancies amid efforts to secure a new industry.Some support1 report
-
The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Some support1 report
-
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Some support2 reports4 developments inside
-
International agency reports cancer statistics in the Philippines, with MSD and Roche supporting an advocacy summit.Some support1 report
-
Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.Well supported6 reports1 development inside
-
The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.Some support1 report
-
Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.Some support2 reports2 developments inside
-
Hoffmann-La Roche, the company, has historical ties to Basel, including the fact that Ballmer worked there in 1926.Some support1 report
-
BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.Some support2 reports
-
Genentech collaboration supports Duality Biotherapeutics' DUPAC platform confidence.Some support1 report
-
The FDA granted clearance for a Genotek kit, which is used in conjunction with Hoffmann-La Roche molecular testing.Well supported10 reports1 development inside
-
The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.Some support2 reports
-
Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.Some support1 report
-
Silicon Valley ethos influences corporate culture, exemplified by Marc Tessier-Lavigne's research at Hoffmann-La Roche.Some support1 report
-
A Swiss company bought operations for $1.2 billion, leading to expanding operations into Solano County and affecting county employment.Some support1 report
-
Hoffmann-La Roche is building a facility in Holly Springs, North Carolina.Some support2 reports
One to three months ago
-
BioNTech pulled the plug on the Phase 2 clinical trial involving Hoffmann-La Roche.Some support1 report
-
Hoffmann-La Roche and DualityBio announced a partnership to develop cancer therapeutics, with John Zhu leading DualityBio.Some support1 report
-
EirGenix and Formosa Pharmaceuticals co-develop a biosimilar candidate, TSY-110, which is an alternative to Kadcyla®.Some support1 report
-
Hoffmann-La Roche, AstraZeneca, and Pfizer are participating in local pharmaceutical production projects in Kazakhstan.Some support1 report
-
Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.Some support1 report
-
Hanmi Pharmaceutical, a South Korean company, successfully licensed one of its obesity drug candidates to the multinational giant Hoffmann-La Roche on August 1, 2026.Some support1 report
-
Easing worries about Middle East tensions involving Hoffmann-La Roche.Some support1 report
-
Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.Some support1 report1 development inside
-
Dannielle Appelhans began her career at McKinsey & Company, gained experience, held senior roles, and led a strategic collaboration involving Eli Lilly and Company, Novartis, and Hoffmann-La Roche.Some support1 report
-
Major pharmaceutical companies, including Hoffmann-La Roche and Novartis, are building large production facilities in North Carolina.Some support1 report1 development inside
-
Hoffmann-La Roche entered into a collaboration with an unnamed biopharma company, generating royalty revenue driven by cost reimbursement.Some support1 report1 development inside
-
Hoffmann-La Roche is expected to increase contract manufacturing revenue, including a $40 million milestone payment.Some support1 report
-
The Vanguard International High Dividend Yield ETF holds top positions in companies including Hoffmann-La Roche, HSBC, Novartis, Royal Bank of Canada, and Nestlé, with weak dollar impacting distribution.Some support1 report
-
Nvidia, Eli Lilly, Bristol-Myers Squibb, and Hoffmann-La Roche announced a partnership to build a hybrid-cloud AI factory and powerful AI infrastructure.Some support1 report
-
Lineage's OpRegen RPE cell therapy program was licensed by Roche and Genentech.Some support2 reports
-
Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.Some support2 reports1 development inside
-
Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.Some support1 report
-
Threats of tariffs and restrictive pricing policies involving major companies like Johnson & Johnson, Eli Lilly, and Roche, alongside Congressional planning.Some support4 reports3 developments inside
-
Denali and Hoffmann-La Roche announced the development of new therapies for Parkinson's disease.Some support1 report
-
Hoffmann-La Roche and Cumberland Pharmaceuticals Inc. are being compared for investment.Some support1 report
-
Roche commercialized a treatment after partnering with Sarepta, while Sarepta simultaneously faced a regulatory pause in the U.S.Some support2 reports
-
Novartis, Octapharma, Hoffmann-La Roche, and Siemens announced investments in the U.S. manufacturing sector, citing figures up to $50 billion.Some support1 report
-
A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.Some support1 report1 development inside
-
Hoffmann-La Roche and Recursion utilized an AI platform to identify novel targets, including an advanced neuroscience target, for early discovery.Some support1 report
-
LabCorp is gaining Medicare coverage for its cancer testing offerings, which utilize companion diagnostics from Hoffmann-La Roche.Some support2 reports
-
The foundational DNA cutting research of Herbert Boyer is being reported, having been conducted at the University of California.Some support1 report
-
Corcept Therapeutics submitted an NDA for relacorilant to the FDA and is evaluating it in combination with Roche's Avastin.Well supported4 reports
-
Roche seeks AI expertise for corporate vision while PwC studies trends in the Swiss job market.Some support1 report
-
Leadership appointments support continued growth for Foundation Medicine and Hoffmann-La Roche.Some support1 report
-
ASML, HSBC, and Roche are listed in the iShares Core MSCI EAFE ETF, which focuses on developed international markets.Some support3 reports
-
Several major companies, including Novartis, Roche, and Alcon, reported financial results and experienced stock market movements in Switzerland.Some support1 report
-
Hoffmann-La Roche is gaining access to MaxCyte's platform technologies for cell therapy development.Some support3 reports
-
Major pharmaceutical companies licensed drug delivery technologies like Enhanze and Hypercon for various applications.Some support2 reports
-
Freenome, led by CEO Aaron Elliott, has announced transformative partnerships with both Abbott and Hoffmann-La Roche.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Hoffmann-La Roche this week
News at the entities that move Hoffmann-La Roche most-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves Hoffmann-La Roche
-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Hoffmann-La Roche
-
Recursion (United States) StructuralRecursion (United States) disclosed insider trading via required filings with the SEC on June 6, 2026.Moves Hoffmann-La Roche
-
Merck OperationalEli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Moves Hoffmann-La Roche
-
Pfizer OperationalDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Hoffmann-La Roche
-
Novartis TransactionalNovartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Moves Hoffmann-La Roche
Connections
The 40 strongest of 924, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Halozyme Therapeutics Structural
Roche utilizes Halozyme's ENHANZE drug delivery technology under a licensing agreement, generating royalty payments.
-
Recursion (United States) Structural
The relationship is a critical, ongoing strategic partnership focused on joint drug discovery, generating mutual revenue and candidates.
-
Novo Nordisk Operational
Hoffmann-La Roche and Novo Nordisk are direct competitors in the global obesity and weight-loss drug markets.
-
Sarepta Therapeutics Operational
Sarepta Therapeutics and Hoffmann-La Roche are actively collaborating on the development and contract manufacturing of the Elevidys gene therapy.
-
Alnylam Pharmaceuticals Operational
Alnylam and Roche maintain an ongoing operational partnership involving joint drug development and milestone payments.
-
Basilea Pharmaceutica Structural
Basilea Pharmaceutica was established as a spin-off from Hoffmann-La Roche.
-
Paulo Fontoura Structural
Paulo Fontoura was employed by Hoffmann-La Roche for 15 years.
-
Merck Operational
Roche and Merck are direct competitors in the immuno-oncology and PD-L1 inhibitor markets.
Show all 40 connections
-
Pfizer Operational
Pfizer and Hoffmann-La Roche are key competitors in specialized pharmaceutical markets, including Danon Disease and GLP-1 drug development, and share technology licensing strategies.
-
Herbert Boyer Structural
Hoffmann-La Roche's current research and products are founded upon the specific DNA cutting research conducted by Herbert Boyer.
-
Novartis Transactional
Novartis completed the divestiture by selling its investment stake in Hoffmann-La Roche.
-
Eli Lilly and Company Operational
Hoffmann-La Roche and Eli Lilly and Company are actively collaborating on product development, securing joint market authorizations, and participating in test launches.
-
LabCorp Structural
LabCorp utilizes companion diagnostic tests provided by Hoffmann-La Roche for prostate cancer testing.
-
FDA Structural
The FDA formally regulates Hoffmann-La Roche's pharmaceutical products, requiring product approval and clearance for market access.
-
National Cancer Centre Singapore Structural
The partnership between Roche and the National Cancer Centre Singapore is focused on leveraging combined expertise to accelerate precision medicine research.
-
Lineage Cell Therapeutics Operational
Hoffmann-La Roche and Lineage Cell Therapeutics maintain an exclusive worldwide collaboration for the development and optimization of the OpRegen therapy.
-
Exelixis Operational
Exelixis utilizes Roche's Tecentriq product as part of a combined therapeutic approach.
-
Nvidia Operational
The entities maintain an active operational collaboration focused on developing AI-driven therapeutics and biotech.
-
AstraZeneca Operational
Hoffmann-La Roche and AstraZeneca are direct competitors in the pharmaceutical market, facing shared market pressures and rivalry in drug development.
-
Hanmi Pharmaceutical Structural
Hanmi Pharmaceutical holds a licensing agreement with Roche Group for its obesity drug.
-
TTR Transactional
Hoffmann-La Roche is currently evaluating TTR's technology/product, prasinezumab, for potential application in Parkinson's disease.
-
University of California Structural
Hoffmann-La Roche was founded based on research conducted at the University of California.
-
Johnson & Johnson Operational
Roche and Johnson & Johnson are actively competing in the oncology and generalized myasthenia gravis markets.
-
JAMA Structural
Hoffmann-La Roche utilizes JAMA as a peer-reviewed platform for publishing studies that support its test development.
-
Astex Pharmaceuticals Transactional
Exclusive license granted for breast cancer compounds.
-
Sarawak General Hospital Operational
SGH provides testing services and samples to Hoffmann-La Roche for drug development.
-
Food and Drug Administration Structural
The FDA formally cleared Roche's blood test for Alzheimer's, establishing a regulatory dependency.
-
Genotek Structural
Genotek provides kits that are utilized by Hoffmann-La Roche for molecular testing.
-
OraSure Technologies Structural
OraSure supplies testing kits that are utilized by Hoffmann-La Roche for its procedures.
-
Nigeria Operational
The operational environment of the pharmaceutical supply chain is compromised by the infiltration of counterfeit drugs, affecting both the national market in Nigeria and the global industry standards upheld by Hoffmann-La Roche.
-
Bristol-Myers Squibb Operational
Both companies are direct competitors in the pharmaceutical market, offering drugs for lung cancer and facing comparative market pressures.
-
GSK Operational
The two companies are actively competing in the market, specifically regarding lung cancer treatments.
-
Kazakhstan Structural
Hoffmann-La Roche maintains a functional presence in Kazakhstan through ongoing local production projects.
-
Allston Structural
Hoffmann-La Roche is establishing a research hub in Allston.
-
Boston Structural
Hoffmann-La Roche is establishing a functional and ongoing R&D presence within the city of Boston.
-
Illumina Operational
Illumina and Hoffmann-La Roche are actively competing in the gene sequencing and liquid biopsy markets.
-
Amgen Operational
The companies are active market competitors in the pharmaceutical sector, evidenced by rivalry in bispecific antibodies and past patent transactions.
-
MoSS Operational
The relationship is currently operational, involving A leveraging B's work to increase contract manufacturing revenue.
-
National University of Singapore Operational
Hoffmann-La Roche and National University of Singapore collaborate on genomic profiling research.
-
Democrats Transactional
Hoffmann-La Roche provided campaign contributions to the Democratic political group.
History
Events by the month they beganSeptember 2026
17 events- Hoffmann-La Roche opened a new R&D center in Boston.
- Nvidia and Hoffmann-La Roche share interest in AI-driven therapeutics following the establishment of a new innovation center in Boston.
- Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.
- Earendil Labs collaborates with Genentech.
- Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.
- Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.
- LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.
- Arvinas secured capital via a Genentech partnership, AdvanCell appointed a new CFO, and Johanna Mylet served as an audit manager.
- China's rise in vitamin production is putting pressure on European companies, highlighted by the divestment of Roche's vitamins division.
- A company involving Hoffmann-La Roche is facing imminent closure and 100 redundancies amid efforts to secure a new industry.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- International agency reports cancer statistics in the Philippines, with MSD and Roche supporting an advocacy summit.
- The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.
- Hoffmann-La Roche, the company, has historical ties to Basel, including the fact that Ballmer worked there in 1926.
- BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.
- Genentech collaboration supports Duality Biotherapeutics' DUPAC platform confidence.
- The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.
August 2026
23 events- Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.
- Silicon Valley ethos influences corporate culture, exemplified by Marc Tessier-Lavigne's research at Hoffmann-La Roche.
- A Swiss company bought operations for $1.2 billion, leading to expanding operations into Solano County and affecting county employment.
- Hoffmann-La Roche is building a facility in Holly Springs, North Carolina.
- BioNTech pulled the plug on the Phase 2 clinical trial involving Hoffmann-La Roche.
- Hoffmann-La Roche and DualityBio announced a partnership to develop cancer therapeutics, with John Zhu leading DualityBio.
- EirGenix and Formosa Pharmaceuticals co-develop a biosimilar candidate, TSY-110, which is an alternative to Kadcyla®.
- Hoffmann-La Roche, AstraZeneca, and Pfizer are participating in local pharmaceutical production projects in Kazakhstan.
- Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.
- Hanmi Pharmaceutical, a South Korean company, successfully licensed one of its obesity drug candidates to the multinational giant Hoffmann-La Roche on August 1, 2026.
- Easing worries about Middle East tensions involving Hoffmann-La Roche.
- Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.
- Dannielle Appelhans began her career at McKinsey & Company, gained experience, held senior roles, and led a strategic collaboration involving Eli Lilly and Company, Novartis, and Hoffmann-La Roche.
- Major pharmaceutical companies, including Hoffmann-La Roche and Novartis, are building large production facilities in North Carolina.
- Hoffmann-La Roche is expected to increase contract manufacturing revenue, including a $40 million milestone payment.
- The Vanguard International High Dividend Yield ETF holds top positions in companies including Hoffmann-La Roche, HSBC, Novartis, Royal Bank of Canada, and Nestlé, with weak dollar impacting distribution.
- Nvidia, Eli Lilly, Bristol-Myers Squibb, and Hoffmann-La Roche announced a partnership to build a hybrid-cloud AI factory and powerful AI infrastructure.
- Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.
- Denali and Hoffmann-La Roche announced the development of new therapies for Parkinson's disease.
- Hoffmann-La Roche and Cumberland Pharmaceuticals Inc. are being compared for investment.
- Novartis, Octapharma, Hoffmann-La Roche, and Siemens announced investments in the U.S. manufacturing sector, citing figures up to $50 billion.
- Hoffmann-La Roche and Recursion utilized an AI platform to identify novel targets, including an advanced neuroscience target, for early discovery.
- LabCorp is gaining Medicare coverage for its cancer testing offerings, which utilize companion diagnostics from Hoffmann-La Roche.
July 2026
10 events- Hoffmann-La Roche entered into a collaboration with an unnamed biopharma company, generating royalty revenue driven by cost reimbursement.
- A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.
- The foundational DNA cutting research of Herbert Boyer is being reported, having been conducted at the University of California.
- Roche seeks AI expertise for corporate vision while PwC studies trends in the Swiss job market.
- Leadership appointments support continued growth for Foundation Medicine and Hoffmann-La Roche.
- ASML, HSBC, and Roche are listed in the iShares Core MSCI EAFE ETF, which focuses on developed international markets.
- Several major companies, including Novartis, Roche, and Alcon, reported financial results and experienced stock market movements in Switzerland.
- Hoffmann-La Roche is gaining access to MaxCyte's platform technologies for cell therapy development.
- Major pharmaceutical companies licensed drug delivery technologies like Enhanze and Hypercon for various applications.
- Freenome, led by CEO Aaron Elliott, has announced transformative partnerships with both Abbott and Hoffmann-La Roche.
Show 1 earlier month
June 2026
10 events- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.
- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
- Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.
- Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.
- The FDA granted clearance for a Genotek kit, which is used in conjunction with Hoffmann-La Roche molecular testing.
- Lineage's OpRegen RPE cell therapy program was licensed by Roche and Genentech.
- Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
- Threats of tariffs and restrictive pricing policies involving major companies like Johnson & Johnson, Eli Lilly, and Roche, alongside Congressional planning.
- Roche commercialized a treatment after partnering with Sarepta, while Sarepta simultaneously faced a regulatory pause in the U.S.
- Corcept Therapeutics submitted an NDA for relacorilant to the FDA and is evaluating it in combination with Roche's Avastin.